A statistical framework to systematically characterize cancer driver mutations in noncoding genomic regions
A statistical framework to systematically characterize cancer driver mutations in noncoding genomic regions
批准号:
10260680
负责人:
Eliezer M Van Allen
金额:
$17.7万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2019
资助国家:
美国
项目状态:
已结题
起止时间:
2019-07-01 至 2021-12-31
关键词:
AddressAffectAlgorithmsAlternative SplicingAttentionBinding SitesBiologicalBiological ProcessBiologyClinicalCodeCommunitiesComputational BiologyComputer ModelsDataData SetDevelopmentGene ExpressionGene Expression RegulationGenomic SegmentImmunotherapyKnowledgeMachine LearningMalignant NeoplasmsMediatingMethodsMicrosatellite InstabilityModelingMonte Carlo MethodMutationNucleic Acid Regulatory SequencesNucleotidesOutcomePatientsPatternPlayPositioning AttributeProbabilityProcessRoleSomatic MutationStatistical ModelsStratificationTestingThe Cancer Genome AtlasUntranslated RNAbasecancer genomecancer immunotherapycheckpoint therapyclinical applicationclinical effectcohortdesigndriver mutationepigenomicsexome sequencinggenome sequencinggenome-wideimmune checkpoint blockadeimmunogenicitylarge datasetsmalignant breast neoplasmmelanomamutantneoantigensneoplastic cellnovelopen sourcepredicting responsepromoterprotein functionreference genomeresponsetargeted treatmenttranscription factortumorwhole genome
中文摘要
点击翻译按钮获取中文摘要
英文摘要
PROJECT SUMMARY
Cancer genomes typically harbor a substantial number of somatic mutations. Relatively few driver mutations
actually alter the function of proteins in tumor cells, whereas most mutations are considered to be functionally
neutral passenger mutations. Over the past decade, the search for cancer driver mutations has focused on
coding regions and several mutational significance algorithms have been developed for coding mutations. The
contribution of mutations in noncoding regulatory regions to tumor formation largely remains unknown and
current mutational significance algorithms are not designed to detect driver mutations in noncoding regions, due
to biological differences between coding and noncoding mutations. The emerging availability of large whole-
genome sequencing datasets (e.g. PCAWG and HMF datasets) creates an ample opportunity to develop new
mutational significance algorithms that are particularly designed for the interpretation of noncoding regions.
Recently, we have developed a new statistical approach that identifies driver mutations in coding regions based
on the nucleotide context. Critically, consideration of the nucleotide context around mutations does not require
prior knowledge for functional consequences associated with these mutations. Hence, we hypothesize that
generalizing our nucleotide context model to noncoding regions will uncover novel noncoding driver
mutations that cannot be detected using the mutational significance approaches currently available. For
this purpose, we will develop a statistical framework that incorporates the biological differences between coding
and noncoding mutations and that is specifically designed to detect driver mutations in noncoding regions.
Specifically, we will consider the context-dependent distribution of passenger mutations, modeling of the
background mutation rate, accurately partition the background mutation rate, model the sequence composition
of the reference genome, and account for coverage fluctuation. We will then combine these statistical
components by computing an independent product of their underlying probabilities. We will derive a significance
p-value using a Monte-Carlo simulation approach, and use FDR for multiple hypothesis test correction. This
strategy will allow us to accurately estimate the significance of somatic mutations in noncoding genomic regions.
We will next apply this statistical framework to whole-genome sequencing data of 5,523 tumor patients, thereby
deriving a comprehensive list of candidate driver mutations in noncoding regions. Finally, we will investigate
whether noncoding mutations are overrepresented in transcription factor binding sites, regulate gene expression
levels, induce alternative splicing, or affect epigenomic states. Upon the completion of this project, we will have
developed and applied a statistical framework for discovery of significant somatic mutations in noncoding
regions, and defined the mutational landscape of the non-coding cancer genome. All aspects of the methods
developed and applied in this project will be made open source and developed in an online platform.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Molecular Origins and Evolution to Chemoresistance in Germ Cell Tumors
-
批准号:10773483
-
项目类别:
-
资助金额:$15.38万
-
财政年份:2023
-
负责人:Eliezer M Van Allen
-
依托单位:
Molecular origins and evolution to chemoresistance in germ cell tumors
-
批准号:10443070
-
项目类别:
-
资助金额:$40.99万
-
财政年份:2023
-
负责人:Eliezer M Van Allen
-
依托单位:
The Cellular Geography of Therapeutic Resistance in Cancer
-
批准号:10819853
-
项目类别:
-
资助金额:$124.11万
-
财政年份:2023
-
负责人:Eliezer M Van Allen
-
依托单位:
Dissecting and Predicting Lethal Prostate Cancer using Biologically Informed Artificial Intelligence
-
批准号:10628274
-
项目类别:
-
资助金额:$48.53万
-
财政年份:2023
-
负责人:Eliezer M Van Allen
-
依托单位:
Integrative Somatic and Germline Computational Biology to Redefine Clinical Actionability in Solid Tumors
-
批准号:9913487
-
项目类别:
-
资助金额:$40.72万
-
财政年份:2018
-
负责人:Eliezer M Van Allen
-
依托单位:
Molecular origins and evolution to chemoresistance in germ cell tumors
-
批准号:10379230
-
项目类别:
-
资助金额:$40.72万
-
财政年份:2018
-
负责人:Eliezer M Van Allen
-
依托单位:
Molecular origins and evolution to chemoresistance in germ cell tumors
-
批准号:10084830
-
项目类别:
-
资助金额:$40.72万
-
财政年份:2018
-
负责人:Eliezer M Van Allen
-
依托单位:
Integrative Somatic and Germline Computational Biology to Redefine Clinical Actionability in Solid Tumors
-
批准号:10160834
-
项目类别:
-
资助金额:$40.72万
-
财政年份:2018
-
负责人:Eliezer M Van Allen
-
依托单位:
Integrative Somatic and Germline Computational Biology to Redefine Clinical Actionability in Solid Tumors
-
批准号:9517271
-
项目类别:
-
资助金额:$40.72万
-
财政年份:2018
-
负责人:Eliezer M Van Allen
-
依托单位:
Integrative Somatic and Germline Computational Biology to Redefine Clinical Actionability in Solid Tumors
-
批准号:10396664
-
项目类别:
-
资助金额:$40.72万
-
财政年份:2018
-
负责人:Eliezer M Van Allen
-
依托单位:
Resistance to Emerging Androgen Deprivation Therapies in Prostate Cancer
-
批准号:9121500
-
项目类别:
-
资助金额:$17.71万
-
财政年份:2014
-
负责人:Eliezer M Van Allen
-
依托单位:
Resistance to Emerging Androgen Deprivation Therapies in Prostate Cancer
-
批准号:8766124
-
项目类别:
-
资助金额:$17.71万
-
财政年份:2014
-
负责人:Eliezer M Van Allen
-
依托单位:
海外基金